• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Flu Shots for Your Patients Aged ≥65 Years: 2 Questions

Commentary
Article

Immunization Awareness Month

Terry Brenneman, MD

Terry Brenneman, MD

Like COVID-19 infections, influenza disease can be particularly deadly to those older than age 65 years. More than 50% of seasonal hospitalizations and 70% of the annual deaths related to flu occur in this age group. All infectious disease experts agree: flu vaccines are the best protection. There are currently 10 influenza vaccines in the US. Which one(s) should you be using?

Question 1. Which of the following is a current Centers for Disease Control and Prevention (CDC) recommendation about choice of influenza vaccine?


Question 2. Which of the following is true regarding the theoretical basis for the increased effectiveness of Fluzone High-Dose, FluBlock, and Fluad in older adults?


Related Content
Shingrix Nearly 80% Effective Against Shingles in Older Adults up to 11 Years Post-Vaccination / Image credit: ©Sherry Young/AdobeStock

Shingrix Nearly 80% Effective Against Shingles in Older Adults up to 11 Years Post-Vaccination

April 18th 2024
Article

Vaccine efficacy remained high at 82% at year 11 following vaccination, according to new long-term data.

RSV Disease Severity Comparable to Unvaccinated COVID-19, Flu: Daily Dose / image credit: ©New Africa/AdobeStock

RSV Disease Severity Comparable to Unvaccinated COVID-19, Flu: Daily Dose

April 18th 2024
Article

Your daily dose of the clinical news you may have missed.

GSK Announces FDA PDUFA Date for 5-in-1 Meningococcal Vaccine / image credit GSK vaccines: ©desertsands/stock.adobe.com

GSK Announces FDA PDUFA Date for 5-in-1 Meningococcal Vaccine Based on Acceptance of BLA

April 17th 2024
Article

The FDA expects to take action on the GSK BLA for its pentavalent MenB vaccine by February 14, 2025.

New Research Suggests Cardiac Events are Prevalent in Older Adults Hospitalized with RSV / Image credit: ©Kateryna Kon/AdobeStock

New Research Suggests Cardiac Events are Prevalent in Older Adults Hospitalized with RSV

April 16th 2024
Article

Nearly one-quarter of hospitalized adults aged 50 years and older with RSV experienced an acute cardiac event, according to results of a new study.

RSV Disease Severity Comparable to Unvaccinated COVID-19, Influenza: New Research / image credit older man in hospital ©auremar/stock.adobe.com

RSV Disease Severity Comparable to Unvaccinated COVID-19, Influenza: New Research

April 11th 2024
Article

In adults hospitalized with RSV, odds of severe outcomes, including death, were much higher than for those admitted for, but vaccinated against, COVID-19, flu.

Pfizer: MONeT Study Topline Data Positive for Abrysvo in Adults Aged 18 to 59 Years at High Risk for RSV-LRTD / image credit Pfizer logo: cbies/stock.adobe.com

Pfizer: MONeT Study Topline Data Positive for Abrysvo in Adults Aged 18 to 59 Years at High Risk for RSV-LRTD

April 9th 2024
Article

Pfizer plans to submit the phase 3 MONeT data to regulatory bodies in support of an expanded label for Abrysvo to include adults aged 18 to 59, the company said.

© 2024 MJH Life Sciences

All rights reserved.